對于將切斷迷走神經用于治療慢性阻塞性肺疾病的不同意見_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 何權瀛

北京大學人民醫院呼吸科（北京 100083）;

Corresponding?author：

何權瀛, Email: hxk313@126.com

Keywords：

DOI：

10.7507/1671-6205.202204067

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 何權瀛. 對于將切斷迷走神經用于治療慢性阻塞性肺疾病的不同意見. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(7): 457-458. doi: 10.7507/1671-6205.202204067 Copy

1.	黃永康, 張文宇, 黃建安. 靶肺去神經療法在慢性阻塞性肺疾病中的應用進展. 中國呼吸與危重監護雜志, 2021, 20(11): 821-823.
2.	Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2163-2172.
3.	Slebos DJ, Klooster K, Koegelenberg CF, et al. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax, 2015, 70(5): 411-419.
4.	Valipour A, Shah PL, Pison C, et al. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. Respiration, 2019, 98(4): 329-339.
5.	Slebos DJ, Shah PL, Herth FJF, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am J Respir Crit Care Med, 2019, 200(12): 1477-1486.
6.	李為民, 劉倫旭. 呼吸系統疾病基礎與臨床. 北京: 人民衛生出版社, 2017, 11.
7.	Kistemaker LE, Slebos DJ, Meurs H, et al. Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J, 2015, 46(5): 1489-1492.

1. 黃永康, 張文宇, 黃建安. 靶肺去神經療法在慢性阻塞性肺疾病中的應用進展. 中國呼吸與危重監護雜志, 2021, 20(11): 821-823.
2. Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2163-2172.
3. Slebos DJ, Klooster K, Koegelenberg CF, et al. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax, 2015, 70(5): 411-419.
4. Valipour A, Shah PL, Pison C, et al. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. Respiration, 2019, 98(4): 329-339.
5. Slebos DJ, Shah PL, Herth FJF, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am J Respir Crit Care Med, 2019, 200(12): 1477-1486.
6. 李為民, 劉倫旭. 呼吸系統疾病基礎與臨床. 北京: 人民衛生出版社, 2017, 11.
7. Kistemaker LE, Slebos DJ, Meurs H, et al. Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J, 2015, 46(5): 1489-1492.

Next Article
Inflammatory markers of oropharynx in the stable phase of chronic obstructive pulmonary disease

Chinese Journal of Respiratory and Critical Care Medicine

對于將切斷迷走神經用于治療慢性阻塞性肺疾病的不同意見

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content